Disrupting the Autoimmune Disease Treatment Paradigm – Transient, Potent, & Scalable eRNA-based In Vivo CD19 CAR-T Therapy
- Leveraging circular eRNA therapeutics and t-LNPs to drive potent, transient in vivo CAR-T cell engineering
- Revolutionizing the autoimmune treatment paradigm by achieving deep B-cell depletion and “immune reboot” with a non-integrative product
- Replacing ex vivo manufacturing with scalable, off-the-shelf IV-dosed therapy, eliminating the need for lymphoablation